Ashland Inc. ASH
Nov 4, 2026, 3:21 PM EST
- YTD
- +27.82%
- 1 year
- +56.75%
- Market cap
- 3.43B
- Revenue (ttm)
- 1.84B
- Profit margin
- 2.82%
- EPS (ttm)
- 1.56
- Shares out
- 45.79M
- P/E ratio
- 48.08
- Forward P/E
- 16.89
- Dividend
- 1.68 (2.31%)
- Ex-dividend date
- Aug 31, 2026
- YTD return
- +27.82%
- 1-year return
- +56.75%
- Volume
- 448.02K
- Avg volume
- 602.13K
- Open
- 73.54
- Previous close
- 73.02
- Day's range
- 73.26 – 76.30
- 52-week range
- 47.12 – 78.25
- Beta
- 0.36
- Analysts
- Buy
- Price target
- 80.45 (+7.3%)
- Earnings date
- Feb 1, 2027
5D +1.68 (+2.30%)
Key statistics
- Enterprise value
- 4.43B
- PEG ratio
- 1.23
- Price / sales
- 1.81
- Price / book
- 1.79
- Dividend yield
- 2.26%
- Payout ratio
- 106.73%
- Revenue growth
- 7.30%
- Free cash flow
- 269.12M
- Total cash
- 440.00M
- Total debt
- 1.48B
- Return on equity
- 3.99%
- Short % of float
- 12.48%
- 50-day average
- 71.50
- 200-day average
- 63.79
Analyst view
Consensus: buy
- Target (low)
- 73.00
- Target (mean)
- 80.45
- Target (high)
- 90.00
- Strong buy1
- Buy8
- Hold3
- Sell0
- Strong sell0
Next earnings
Feb 1, 2027
Expected Feb 1, 2027. Consensus EPS estimate 1.27.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 1, 2027 | Dec 30, 2026 | 0.34 | — | — | — |
| Nov 3, 2026 | Sep 30, 2026 | 1.27 | 1.12 | -0.15 | -11.81% |
| Jul 28, 2026 | Jun 30, 2026 | 0.985 | 1.02 | +0.04 | +3.55% |
| Apr 28, 2026 | Mar 31, 2026 | 0.97 | 0.91 | -0.06 | -6.19% |
| Feb 2, 2026 | Dec 31, 2025 | 0.23 | 0.26 | +0.03 | +13.04% |
| Nov 4, 2025 | Sep 30, 2025 | 1.17 | 1.08 | -0.09 | -7.69% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 2026 | UBS | main | Buy | Buy |
| Aug 6, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Jul 31, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Jul 30, 2026 | UBS | main | Buy | Buy |
| Jul 30, 2026 | Evercore ISI Group | main | In-Line | In-Line |
| Jul 29, 2026 | Mizuho | main | Outperform | Outperform |
About Ashland Inc.
Ashland Inc. provides additives and specialty ingredients in the North and Latin America, Europe, Asia Pacific, and internationally. It operates through Life Sciences, Personal Care, Specialty Additives, and Intermediates segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; and nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives; agricultural chemicals; diagnostic films; and fine chemicals. Its Personal Care segment provides a range of natural, nature-derived, biodegradable, and performance ingredients; solutions for toothpastes, mouth washes and rinses, denture cleaning, and care for teeth; and household supplies nature-derived rheology ingredients, biodegradable surface wetting agents, performance encapsulates, and specialty polymers. The Specialty Additives segment offers rheology modifiers, foam control agents, surfactants and wetting agents, pH neutralizers, advanced ceramics used in catalytic converters, environmental filters, ingredients for the manufacturing of ceramic capacitors, plasma display panels and solar cells, ingredients for textile printing, thermoplastic metals, and alloys for welding. Its Intermediates segment produces 1,4 butanediol and related derivatives, including n-methylpyrrolidone. It offers its products to customers in a range of consumer and industrial markets, such as architectural coatings, construction, energy, food and beverage, personal care, and pharmaceutical. The company was formerly known as Ashland Global Holdings Inc. and changed its name to Ashland Inc. in August 2022. Ashland Inc. was founded in 1924 and is headquartered in Wilmington, Delaware.
- Sector
- Basic Materials
- Industry
- Specialty Chemicals
- Country
- United States
- Website
- ashland.com
News
Ashland Q4 2026 Earnings Call Transcript
Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026
Actinium Pharmaceuticals Announces Three ASH 2026 Abstracts Highlighting Iomab-ACT Clinical Results in CAR T-Cell Therapy and Sickle Cell Disease
Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting
Actinium Pharmaceuticals Announces ASH 2026 Abstract Highlighting Long-Term Results of Actimab-A in Combination with CLAG-M in Relapsed or Refractory AML
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition
Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026
Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)
CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition
Your note
Sign in to keep a note on ASH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ASSIS ALESSANDRA FACCIN | Officer | Conversion of Exercise of derivative security | Jul 26, 2026 | 8,215 |
| BONI ERIC N. | Officer | Sale | Dec 4, 2024 | 22,319 |
| BOSTAPH KARL R | Officer | Conversion of Exercise of derivative security | Nov 18, 2024 | 7,012 |
| DRURY EILEEN | Officer | Conversion of Exercise of derivative security | Nov 16, 2025 | 7,601 |
| KULKARNI ASHISH K | Director | Conversion of Exercise of derivative security | Jan 20, 2026 | 2,113 |
| LAMPKIN ROBIN E | General Counsel | Conversion of Exercise of derivative security | Aug 10, 2026 | 7,164 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 12.47% | 5,712,189 | 416.70M | Jun 29, 2026 |
| Standard Investments LLC | 9.88% | 4,525,001 | 330.10M | Jun 29, 2026 |
| Franklin Resources, Inc. | 7.90% | 3,616,479 | 263.82M | Jun 29, 2026 |
| Dimensional Fund Advisors LP | 5.43% | 2,486,307 | 181.38M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.38% | 2,462,838 | 179.66M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.50% | 2,063,055 | 150.50M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Value Investors Trust-FRANKLIN SMALL CAP VALUE FUND | 4.02% | 1,841,188 | 134.31M | Jul 30, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.56% | 1,629,402 | 118.86M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.18% | 1,454,480 | 106.10M | Jun 29, 2026 |
| MFS SERIES TRUST XI-MFS Mid Cap Value Fund | 2.80% | 1,283,827 | 93.66M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.62% | 1,201,351 | 87.64M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.30% | 1,051,330 | 76.69M | Jun 29, 2026 |
Dividends
| Ex-dividend date | Amount |
|---|---|
| Sep 1, 2026 | 0.42 |
| Jun 1, 2026 | 0.42 |
| Feb 27, 2026 | 0.415 |
| Dec 1, 2025 | 0.415 |
| Aug 29, 2025 | 0.415 |
| May 30, 2025 | 0.415 |
Splits
| Date | Ratio |
|---|---|
| May 15, 2017 | 511:250 |
| Jul 1, 2005 | 10000:8212 |
| Jun 30, 2005 | 1.21773:1 |
| Mar 30, 2000 | 10000:9465 |
| Mar 29, 2000 | 1.05652:1 |
| Jul 29, 1988 | 2:1 |
